Kowa Company, Ltd.
Clinical trials sponsored by Kowa Company, Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for stubborn high cholesterol: pemafibrate trial launches Results expected Jul 2027 (estimated)
-
New drug offers hope for Statin-Intolerant patients with high cholesterol
Disease control CompletedThis study tested a drug called pemafibrate (K-877) in 71 people with high cholesterol who cannot take statins due to side effects. Participants took either a low or high dose of pemafibrate or a placebo daily for 12 weeks. The goal was to see if pemafibrate safely lowers LDL (ba…
Phase 3 • Sponsor: Kowa Company, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New Once-Daily pill aims to lower high triglycerides
Disease control CompletedThis study tested a new extended-release form of pemafibrate (K-877) in 121 adults with high triglycerides, a type of fat in the blood. Participants took the drug once daily for 52 weeks, either in the morning or evening, to see if it safely lowers triglyceride levels and improve…
Phase 3 • Sponsor: Kowa Company, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill for high cholesterol shows promise in early trial
Disease control CompletedThis study tested a new controlled-release version of the drug pemafibrate in 60 adults with dyslipidemia (abnormal levels of fats in the blood). The goal was to see if the new version works as well or better than the current immediate-release tablet, with fewer side effects. Par…
Phase 2 • Sponsor: Kowa Company, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC